The US Food and Drug Administration is scheduled to share results of the New Drug Application for Bristol Myers Squibb’s KarXT for the treatment of schizophrenia. KarXT is a novel muscarinic acetylcholine receptor agonist. How comfortable do you feel in your knowledge of this type of treatment? Tell us here!

How much do you know about muscarinic receptor agonists?

I feel very educated about this type of treatment.

I feel somewhat educated about this type of treatment.

I feel somewhat uneducated about this type of treatment.

I feel very uneducated about this type of treatment.

If you feel uneducated about muscarinic receptor agonists, what do you want to know? Let us know by emailing us at PTEditor@MMHGroup.com!